Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q2
$594K Buy
2,437
+30
+1% +$7.38K 0.11% 78
2021
Q1
$599K Buy
2,407
+90
+4% +$21.5K 0.13% 62
2020
Q4
$533K Buy
2,317
+1,080
+87% +$249K 0.11% 70
2020
Q3
$314K Hold
1,237
0.09% 78
2020
Q2
$292K Sell
1,237
-20
-2% -$4.56K 0.09% 76
2020
Q1
$255K Hold
1,257
0.11% 76
2019
Q4
$303K Buy
1,257
+140
+13% +$30.9K 0.09% 85
2019
Q3
$216K Buy
+1,117
New +$214K 0.07% 101
2019
Q2
Sell
-1,167
Closed -$222K 110
2019
Q1
$222K Buy
1,167
+125
+12% +$23.9K 0.07% 101
2018
Q4
$203K Buy
1,042
+30
+3% +$5.85K 0.07% 100
2018
Q3
$210K Buy
+1,012
New +$199K 0.07% 111

Other funds holding AMGN

ARS Wealth Advisors's AMGN Position: Q2 2021 in Review

ARS Wealth Advisors increased its Amgen (AMGN) stake by 1.2% in Q2 2021, buying an estimated $7.38K and bringing the position to 2,437 shares worth $594K. The position accounts for 0.11% of the portfolio, ranked #78.

ARS Wealth Advisors first reported a position in AMGN in Q3 2018 and has held it in 11 quarters since. The position peaked at $599K in Q1 2021. 2,195 funds tracked by Wall St. Rank hold AMGN as of Q2 2021.

  • ARS Wealth Advisors held 2,437 shares of Amgen worth $594K as of Q2 2021.
  • ARS Wealth Advisors bought 30 Amgen shares in Q2 2021, an estimated $7.38K.
  • Amgen made up 0.11% of ARS Wealth Advisors's portfolio in Q2 2021, its #78 holding.
  • ARS Wealth Advisors first reported a position in Amgen in Q3 2018 and has held it in 11 quarters since.
  • ARS Wealth Advisors's Amgen position peaked at $599K in Q1 2021.
  • 2,195 funds tracked by Wall St. Rank held Amgen as of Q2 2021.

Based on ARS Wealth Advisors's 13F filing for Q2 2021, filed 15 Jul 2021.